R
Randy Q. Cron
Researcher at University of Alabama at Birmingham
Publications - 240
Citations - 12442
Randy Q. Cron is an academic researcher from University of Alabama at Birmingham. The author has contributed to research in topics: Arthritis & Macrophage activation syndrome. The author has an hindex of 52, co-authored 217 publications receiving 10114 citations. Previous affiliations of Randy Q. Cron include Children's Hospital of Philadelphia & University of Pennsylvania.
Papers
More filters
Journal ArticleDOI
2011 American College of Rheumatology Recommendations for the Treatment of Juvenile Idiopathic Arthritis: Initiation and Safety Monitoring of Therapeutic Agents for the Treatment of Arthritis and Systemic Features
Timothy Beukelman,Nivedita M. Patkar,Kenneth G. Saag,Sue Tolleson-Rinehart,Randy Q. Cron,Esi Morgan DeWitt,Norman T. Ilowite,Yukiko Kimura,Ronald M. Laxer,Daniel J. Lovell,Alberto Martini,C. Egla Rabinovich,Nicolino Ruperto +12 more
TL;DR: Guidelines and recommendations developed and/or endorsed by the American College of Rheumatology are intended to provide guidance for particular patterns of practice and not to dictate the care of a particular patient.
Journal ArticleDOI
On the Alert for Cytokine Storm: Immunopathology in COVID-19.
Lauren A. Henderson,Scott W. Canna,Grant S. Schulert,Stefano Volpi,Pui Y. Lee,Kate F. Kernan,Roberto Caricchio,Shawn A. Mahmud,Melissa M. Hazen,Olha Halyabar,Kacie J Hoyt,Joseph Han,Alexei A. Grom,Marco Gattorno,Angelo Ravelli,Fabrizio De Benedetti,Edward M. Behrens,Randy Q. Cron,Peter A. Nigrovic +18 more
TL;DR: While studies are ongoing, extrapolating from clinical experience in cytokine storm syndromes may benefit the multidisciplinary teams caring for patients with severe COVID‐19.
Journal ArticleDOI
2016 Classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: A European league against Rheumatism/American college of Rheumatology/Paediatric rheumatology international trials organisation collaborative initiative
Angelo Ravelli,Francesca Minoia,Sergio Davì,AnnaCarin Horne,Francesca Bovis,Angela Pistorio,Maurizio Aricò,Tadej Avcin,Edward M. Behrens,Fabrizio De Benedetti,Lisa Filipovic,Alexei A. Grom,Jan-Inge Henter,Norman T. Ilowite,Michael B. Jordan,Raju Khubchandani,Toshiyuki Kitoh,Kai Lehmberg,Daniel J. Lovell,Paivi Miettunen,Kim E. Nichols,Seza Ozen,Jana Pachlopnik Schmid,Athimalaipet V Ramanan,Ricardo Russo,Rayfel Schneider,Gary Sterba,Yosef Uziel,Carol A. Wallace,Carine Wouters,Nico M Wulffraat,Erkan Demirkaya,Hermine I. Brunner,Alberto Martini,Nicolino Ruperto,Randy Q. Cron +35 more
TL;DR: Criteria for the classification of macrophage activation syndrome (MAS) in patients with systemic juvenile idiopathic arthritis (JIA) is developed.
Journal ArticleDOI
The Immunology of Macrophage Activation Syndrome.
TL;DR: In addition to broadly immunosuppressive therapies, novel cytokine targeted treatments are being explored to dampen the overly active immune response that is responsible for much of the pathology seen in MAS.
Journal ArticleDOI
Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series
Peter A. Nigrovic,Melissa L. Mannion,Femke H. M. Prince,Andrew Zeft,C. Egla Rabinovich,Marion A J van Rossum,Elisabetta Cortis,Manuela Pardeo,Paivi Miettunen,Ginger Janow,James Birmingham,Aaron Eggebeen,Erin Janssen,Andrew I. Shulman,Mary Beth F. Son,Sandy D. Hong,Karla N. Jones,Norman T. Ilowite,Randy Q. Cron,Gloria C. Higgins +19 more
TL;DR: Anakinra as first-line therapy for systemic JIA was associated with rapid resolution of systemic symptoms and prevention of refractory arthritis in almost 90% of patients during the interval examined.